MedPath

A Clinical and Biological Research of Combined Chinese and Western Medicine in the Treatment of PCOS

Phase 2
Conditions
PCOS
Interventions
Drug: Dingkundan & Diane-35
Registration Number
NCT03264638
Lead Sponsor
Aijun Sun
Brief Summary

This study evaluates the effects and biological mechanisms of Dingkundan,Diane-35 and the combination of Dingkundan and Diane-35 in the treatment of polycystic syndrome(PCOS) in adults women. One third of participants will receive Dingkundan capsules, one third of participants will receive Diane-35 Pills, and the another third will receive Dingkundan capsules and Diane-35 in combination.

Detailed Description

Dingkundan,Diane-35 each ameliorate PCOS, but they do so by different mechanisms. We generally treat PCOS patients without immediate fertility requirement by short-acting contraceptives,Diane-35 is one of the most commonly used drugs.

Dingkundan consists of multiple chinese herbs including ginseng,Panax notoginseng,deer antlers,Carthamus tinctorius L.,Radix Paeoniae Alba,prepared Radix Rehmanniae,Angelica etc., which gains widespread application in the treatment of gynecological diseases. Based on the characteristics above, we try to explore its clinical application value in PCOS and its biological mechanisms.

Recruitment & Eligibility

Status
UNKNOWN
Sex
Female
Target Recruitment
315
Inclusion Criteria
  • Subject is a female between the age of 18 and 40.
  • Subject diagnosed as PCOS by the 2003 Rotterdam criteria.
  • Subject provides written informed consent.
Exclusion Criteria
  • Subject has other endocrine diseases,such as adrenal hyperplasias or tumor, androgen-secreting tumours, Cushing's syndrome,thyroid diseases and hyperprolactinemia.
  • Subject has received related medical or surgical treatment in the past 3 months.
  • Subject suffered from substance abuse or dependence(such as alcohol or drugs);
  • Subject is a heavy smoker(reaching or more than 20 cigarettes a day).
  • Subject is pregnant or lactating or within 1 year after delivery.
  • Subject has a severe systemic disease, such as cardiovascular system
  • Subject has a history of malignancy or radiotherapy.
  • Subject has an allergic history to the drugs used in the study.
  • Subject has mental disorder incapable of elementary cooperations.
  • Subject has participated in other clinical researches of medicine within 3 month prior to randomization.

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Dingkundan & Diane-35Dingkundan & Diane-35Dingkundan 7g capsule by mouth, twice daily, and Diane-35 one pill by mouth, once daily, beginning on Day 5 of menstrual cycle for 21 consecutive days followed by a 7-day interval without medication; for three cycles
Diane-35Diane-35Diane-35 one pill by mouth,once daily, beginning on Day 5 of menstrual cycle for 21 consecutive days followed by a 7-day interval without medication; for three cycles
DingkundanDingkundanDingkundan 7g capsule by mouth, twice daily, beginning on Day 5 of menstrual cycle for 21 consecutive days followed by a 7-day interval without medication; for three cycles
Primary Outcome Measures
NameTimeMethod
symptoms5 minutes

PCOS symptoms

sex hormone levels changes5 minutes

sex hormone levels changes

Secondary Outcome Measures
NameTimeMethod
lipid metabolism5 minutes

blood lipid profile

metabolites figure spectrum5 minutes

metabolites figure spectrum to undermine the mechanism of Dingkundan and Diane-35 in the treatment of PCOS

Fasting insulin5 minutes

Fasting insulin

glycosylated hemoglobin5 minutes

glycosylated hemoglobin

fasting blood glucose5 minutes

fasting blood glucose

Trial Locations

Locations (1)

Lei Li

🇨🇳

Beijing, China/Beiing, China

© Copyright 2025. All Rights Reserved by MedPath